United States Patent (19) 11) 4,296,104 Herschler 45) Oct
Total Page:16
File Type:pdf, Size:1020Kb
United States Patent (19) 11) 4,296,104 Herschler 45) Oct. 20, 1981 (54) THERAPEUTIC DIMETHYL SULFOXIDE 3,743,727 7/973 Herschler ............................ 424/181 COMPOSITION AND METHODS OF USE 4,112,946 9/1978 Herschler ............................ 128/253 4,177,267 12/1979 Herschler ............................ 424/238 76) Inventor: Robert J. Herschler, 3080 N.W. 8th St., Camas, Wash. 98.607 OTHER PUBLICATIONS (21) Appl. No.: 71,072 Mallach, 141, Annals New York Academy of Sciences, pp. 457-462. 22 Filed: Aug. 30, 1979 Primary Examiner-Stanley J. Friedman 51) Int. Cl...................... A61K 31/10; A61K 31/17; Attorney, Agent, or Firm-Blakely, Sokoloff, Taylor & A61K 33/14 Zafman 52 U.S. C. .................................... 424/153; 424/322; 424/337 57 ABSTRACT 58 Field of Search ........................ 424/322, 153, 337 The use of urea and/or ethanol with pharmaceutical 56) References Cited compositions containing DMSO is disclosed. The result is a reduction in the undesirable side-effects normally U.S. PATENT DOCUMENTS associated with the application of DMSO compositions, 3,334,012. 8/1967 Herschler ............. ... 424/337 enhancement of the desired physiological effects pro 3,361,555 l/1968 Herschler .............................. 71/103 duced by DMSO compositions, and other benefits. Spe 3,499,961 3/1970 Dobson et al. ....................... 424/68 cific compositions contain DMSO with urea and/or 3,549,770 12/1970 Herschler ..... ... 424/337 alcohol and may also contain NaCl, KCl and/or acet 3,549,771 12/1970 Herschler ..... ... 424/337 amide. 3,551,554 12/1970 Herschler ................................ 424/7 3,558,434 1/1971 Herschler .............................. 195/81 The use of DMSO to reduce the mortality rate of fish. 3,711,602 1/1973 Herschler .............................. 424/45 treated by hyperosmotic delivery is also disclosed. 3,711,606 1/1973 Herschler .............................. 424/45 3,740,420 1/1973 Herschler .............................. 424/45 8 Claims, No Drawings 4,296,104 1 2 blood cell lysis which results from intravenous DMSO THERAPEUTC DIMETHYL SULFOXIDE administration can be injurious or even fatal to the sub COMPOSITION AND METHODS OF USE ject. Furthermore, it is generally advisable to minimize the BACKGROUND OF THE INVENTION 5 dosage of any pharmaceutical substance administered to The present invention relates to pharmaceutical com a human or other animal subject to the smallest effective positions containing DMSO for adminstration to human amount. Although DMSO is one of the most penetrat or other animal subjects. More specifically, it relates to ing of pharmaceutical substances and is known to be new DMSO formulations containing substances which effective in minute doses, it would be desirable to fur enhance the effectiveness of DMSO, reduce undesirable 10 ther reduce the minimum dosage of DMSO needed to side-effects sometimes created by the use of DMSO and achieve a desired physiological effect. make DMSO compositions more appealing to users. A related problem is observed when fish are treated Dimethyl sulfoxide (DMSO) is a versatile substance with hyperosmotic concentrations of a membrane per that has numerous pharmaceutical and nonpharmaceuti meability altering agent as discussed in U.S. Pat. No. cal uses. It is widely used throughout the world for 15 treating humans and other animal subjects. 4,112,946, incorporated herein by reference. Such As Described in U.S. Pat. No. 3,549,770, No. agents include urea, NaCl and acetamide. 3,740,420, and No. 3,790,682, incorporated herein by These substances, with the possible exception of acet the reference, DMSO is an active agent in relieving the amide, are substantially nontoxic when applied exter signs and symptoms of numerous body disorders, in 20 nally to mammalian subjects. But, when incorporated in cluding accelerating the healing of certain injured body a solution in contact with an epithelial membrane of tissues and in relieving the signs and symptoms of anxi fish, such substances can be lethal at moderate concen ety. w trations (as low as about 3 weight percent). U.S. Pat. No. 3,551,554, No. 3,711,606 and No. To optimize delivery of therapeutic agents to fish, 3,743,727, incorporated herein by reference, describe 25 solutions containing greater than 3 weight percent of how DMSO is effective to enhance tissue penetration of the above listed solutes are required. Fish mortality is other substances, especially other physiologically active thus a substantial barrier to the effective use of hyperos agents. DMSO can thus be added to a variety of phar motic treatments. maceutical compositions to accelerate assimilation into SUMMARY OF THE INVENTION body tissue. In some instances this means that smaller 30 doses can be administered when DMSO is used. Specific DMSO compositions and methods of appli Yet, despite their many benefits, DMSO composi cation have now been discovered. Use of such composi tions are sometimes passed over in favor of other phar tions expands the acceptability of DMSO by eliminating maceutical compositions even in instances where or reducing undesirable side-effects. And, the new DMSO would be the most effective pharmaceutical 35 DMSO compositions and methods of use are observed agent. This is because many subjects suffer from one or to provide new therapeutic effects and beneficial uses. more side-effects when treated with DMSO. In some More specifically, it is found that when DMSO and cases, the side-effects are so pronounced that subject or urea are both administered to epithelial regions of a physician will forego the use of DMSO in favor of a less human or other animal subject, expected adverse skin effective therapeutic agent. 40 reactions, malodorous breath and foul taste are substan A variety of undesirable side-effects have been ob tially reduced. In most cases they are entirely elimi served to result from administration of DMSO. The nated. most frequently occurring are adverse skin reactions, Furthermore, urea is discovered to potentiate DMSO malodorous breath and foul taste. in certain instances. It appears that a DMSO composi The adverse reactions caused by DMSO are well 45 documented. At page 356 of the standard reference tion containing urea and/or ethanol is more rapidly Contact Dermatitis by Alexander A. Fisher, M.D. (2nd absorbed into tissue than are similar compositions con Ed., 1973), dimethyl sulfoxide (DMSO) is listed as a taining no urea or ethanol. If the DMSO composition primary urticariogen. Volume 141 of Annals New York includes another pharmaceutical substance, such other Academy of Sciences includes several articles describ 50 substance is also absorbed more rapidly when urea and ing the undesirable side-effects attributed to DMSO. /or ethanol are present. The presence of NaCl, KCl These include articles by Goldman, et al. at pages 429, and/or acetamide reduces discomfort resulting from 433-35; Sulzberger, et al. at pages 439-40; Brown at topical application of DMSO compositions and appears pages 500-501; and several others. to further enhance penetration. The magnitude of the malodorous breath problem is 55 It has also been discovered that certain DMSO for so large that, in some instances, hospitals have had to mulations, which contain urea, are effective in treating isolate wards where DMSO is administered from the diseased finger and toe nails, for softening cuticle to be central air conditioning system. Skin irritations from removed from finger and toe nails, and for softening topically applied DMSO have been so great that a sub epidermal thickenings to ease removal. stantial number of patients refuse treatment. When DMSO is administered intravenously with Another, potentially more serious side-effect is some ethanol, red blood cell lysis is reduced and continues to times observed when DMSO is administered intrave decline with repeated administrations. nously. This is red blood cell lysis, Intravenous adminis When DMSO is added to solutions containing urea, tration of DMSO is crucial if the substance is to be used NaCl, and/or acetamide, such solutions are less toxic to for treating the brain and spinal cord, for cancer ther 65 fish than similar solutions without DMSO. apy or to treat organ hypoxia, heart attack and other It is therefore an object of this invention to provide internal conditions. Large intravenous doses of DMSO pharmaceutical compositions and methods to allow the can have a therapeutic effect for such purposes but red application of DMSO to a human or other animal sub 4,296,104 3 4. ject without creating adverse skin reactions, malodor ceutical agents so that, at a given weight percent of ous breath or foul taste. solute, compositions containing urea in combination A further object is to provide compositions and meth with DMSO, have an enhanced penetrating ability. The ods of application whereby the lysis of red blood cells, effect is even greater if the amount of solute is increased resulting from intravenous administration of DMSO, is by addition of urea to the DMSO composition. reduced. It appears that the only suitable substances for en A further object is to provide compositions and meth hancing the penetration of DMSO compositions are ods of treatments for diseases of the fingers and/or toe substances having a weight per volume percentage nails. concentration at isotonicity less than that of DMSO, but Another object is to provide formulations and meth 10 only a few of such substances produce the desired in ods of application to enhance penetration of DMSO and crease in penetration. DMSO based pharmaceutical compositions into animal Further criteria of substances which enhance DMSO tissue. penetration include water solubility at ambient tempera An additional object is to provide safe and effective tures and a molecular weight no greater than 78. Sub skin softening agents which can be used to soften cuticle 15 stances which tend to polymerize are unsuitable. If the for removal from finger and/or toe nails and for soften substance is to be used with DMSO-urea compositions ing epidermal thickenings to facilitate removal.